EPS for Conformis, Inc. (CFMS) Expected At $-0.20

October 14, 2018 - By Winifred Garcia

Conformis, Inc. (NASDAQ:CFMS) Logo

Analysts expect Conformis, Inc. (NASDAQ:CFMS) to report $-0.20 EPS on November, 7.They anticipate $0.09 EPS change or 31.03 % from last quarter’s $-0.29 EPS. After having $-0.24 EPS previously, Conformis, Inc.’s analysts see -16.67 % EPS growth. The stock increased 2.22% or $0.02 during the last trading session, reaching $0.92. About 97,905 shares traded. Conformis, Inc. (NASDAQ:CFMS) has declined 70.91% since October 14, 2017 and is downtrending. It has underperformed by 86.53% the S&P500.

ConforMIS, Inc., a medical technology company, develops, makes, and sells customized joint replacement implants. The company has market cap of $58.12 million. The firm offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product for treatment of the medial or lateral compartment of the knee, as well as provides iJigs, customized single-use patient-specific instruments. It currently has negative earnings. It is also developing iTotal Hip, a customized total hip replacement implant.

Another recent and important Conformis, Inc. (NASDAQ:CFMS) news was published by Globenewswire.com which published an article titled: “Conformis Announces Settlement of Patent Dispute with Smith & Nephew” on September 17, 2018.

Conformis, Inc. (NASDAQ:CFMS) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>